132 related articles for article (PubMed ID: 21554107)
1. Intravesical interleukin-15 gene therapy in an orthotopic bladder cancer model.
Matsumoto K; Kikuchi E; Horinaga M; Takeda T; Miyajima A; Nakagawa K; Oya M
Hum Gene Ther; 2011 Nov; 22(11):1423-32. PubMed ID: 21554107
[TBL] [Abstract][Full Text] [Related]
2. Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.
Horiguchi Y; Larchian WA; Kaplinsky R; Fair WR; Heston WD
Gene Ther; 2000 May; 7(10):844-51. PubMed ID: 10845722
[TBL] [Abstract][Full Text] [Related]
3. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer.
Larchian WA; Horiguchi Y; Nair SK; Fair WR; Heston WD; Gilboa E
Clin Cancer Res; 2000 Jul; 6(7):2913-20. PubMed ID: 10914741
[TBL] [Abstract][Full Text] [Related]
5. Nonviral cytokine gene therapy on an orthotopic bladder cancer model.
Wu Q; Mahendran R; Esuvaranathan K
Clin Cancer Res; 2003 Oct; 9(12):4522-8. PubMed ID: 14555526
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
7. Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors.
Zang Z; Mahendran R; Wu Q; Yong T; Esuvaranathan K
Int J Mol Med; 2004 Oct; 14(4):713-7. PubMed ID: 15375606
[TBL] [Abstract][Full Text] [Related]
8. IL-23 gene therapy for mouse bladder tumour cell lines.
Kuramoto T; Fujii R; Nagai H; Belladonna ML; Yoshimoto T; Kohjimoto Y; Inagaki T; Hara I
BJU Int; 2011 Sep; 108(6):914-21. PubMed ID: 21435151
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer.
Yu DS; Lee CF; Hsieh DS; Chang SY
Urology; 2004 Mar; 63(3):596-601. PubMed ID: 15028475
[TBL] [Abstract][Full Text] [Related]
10. Postoperative immuno-gene therapy of murine bladder tumor by in vivo administration of retroviruses expressing mouse interferon-gamma.
Shiau AL; Lin CY; Tzai TS; Wu CL
Cancer Gene Ther; 2001 Jan; 8(1):73-81. PubMed ID: 11219496
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
[TBL] [Abstract][Full Text] [Related]
12. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies.
Watanabe T; Shinohara N; Sazawa A; Harabayashi T; Ogiso Y; Koyanagi T; Takiguchi M; Hashimoto A; Kuzumaki N; Yamashita M; Tanaka M; Grossman HB; Benedict WF
Cancer Gene Ther; 2000 Dec; 7(12):1575-80. PubMed ID: 11228536
[TBL] [Abstract][Full Text] [Related]
13. Induction of antitumor immunity with combination of HER2/neu DNA vaccine and interleukin 2 gene-modified tumor vaccine.
Chen SA; Tsai MH; Wu FT; Hsiang A; Chen YL; Lei HY; Tzai TS; Leung HW; Jin YT; Hsieh CL; Hwang LH; Lai MD
Clin Cancer Res; 2000 Nov; 6(11):4381-8. PubMed ID: 11106257
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response.
Furukawa J; Hara I; Nagai H; Yao A; Oniki S; Fujisawa M
J Urol; 2006 Sep; 176(3):1198-203. PubMed ID: 16890725
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
16. Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model.
Terao S; Shirakawa T; Goda K; Kamidono S; Fujisawa M; Gotoh A
Anticancer Res; 2005; 25(4):2757-60. PubMed ID: 16080522
[TBL] [Abstract][Full Text] [Related]
17. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
Loskog AS; Fransson ME; Totterman TT
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8816-21. PubMed ID: 16361570
[TBL] [Abstract][Full Text] [Related]
18. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
[TBL] [Abstract][Full Text] [Related]
19. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer.
Loskog A; Björkland A; Brown MP; Korsgren O; Malmström PU; Tötterman TH
J Urol; 2001 Sep; 166(3):1093-7. PubMed ID: 11490305
[TBL] [Abstract][Full Text] [Related]
20. Cytokine gene modification of bladder cancer cells for the establishment of bladder cancer vaccine.
Saito S; Tazaki H; Heston WD; Fair WR
Int J Urol; 1996 Jan; 3(1 Suppl):S35-9. PubMed ID: 24304018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
